PER

0.00%

10.5¢ percheron therapeutics limited

Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor, page-34

First 34 Last

Share
Profile

Follow
Drian

224 Posts.

27

03/06/24

17:19

Post #: 74142406
Share

Originally posted by Vinceanna: ↑

The Management is burst of confidence for sure ….
It’s certainly building up momentum as we're one step closer to 2nd half the year…

Within the next 3-6 months, we should have the final data of the 9-months toxicology study of ATL1102, everything will unfold:
a) Discuss results with FDA, with a view to lifting clinical hold in the US.
b) Apply for expedited program status with the FDA including Fast Track or potential Breakthrough Therapy designation.
c) By end of the year, we will have Phase IIB Primary Endpoint PUL2.0 score result, if positive, will discuss with FDA on accelerated regulatory pathways to registration.
d) Combination therapy (potential use in ambulant boys – positive data in mdx mice: Have synergistic effect) under strategic consideration.
e) & LGMDR2 is also under strategic consideration (From annual report 2023)
f) Multiple Sclerosis & Acromegaly under Strategic Review (CY2024)
g) Undisclosed Indications under Strategic Review (CY2024)
h) Partnership with any of the above (c-g, hopefully). – Dr James Garner is looking to partner with 1 or more larger companies. (2 unlicenced products)

Key takeaways in today’s announcement (in my opinion):
1. The team is turning its attention to next steps, including potential engagement with regulatory agencies such as FDA
2. Prepare for the next chapter in the development of ATL1102
3. Cathryn’s extensive networks among clinicians and patient advocacy in the US
4. Momentum grows in the ATL1102 program

Looking forward to the NEXT big announcement…

Expand

i am new to PER - can someone please explain this clinical hold in USA?

PER Price at posting: 8.9¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 96 more messages in this thread...

First 34 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	9.8¢	$58.09K	574.8K

Buyers (Bids)

No.	Vol.	Price($)
1	38503	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	194063	5

View Market Depth

No.	Vol.	Price($)
1	100000	0.099
2	108491	0.098
1	30927	0.097
1	10004	0.096
3	162157	0.095

Price($)	Vol.	No.
0.105	194063	5
0.110	254663	3
0.115	1334300	6
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PER (ASX) Chart

Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor, page-34

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor, page-34

Top Stories

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News